BMC Musculoskeletal Disorders (May 2010)

Gel-type autologous chondrocyte (Chondron™) implantation for treatment of articular cartilage defects of the knee

  • Chun Chung-Woo,
  • Cho Jea-Yeong,
  • Seo Yong-Ho,
  • Kim Yoon-Sik,
  • Kim Jin-Soo,
  • Suh Dong-Sam,
  • Kim Haeng-Boo,
  • Yeo Woo-Jin,
  • Kim Byoung-Woo,
  • Choi Nam-Yong,
  • Park Hyun-Shin,
  • Shetty Asode,
  • Kim Seok-Jung

DOI
https://doi.org/10.1186/1471-2474-11-103
Journal volume & issue
Vol. 11, no. 1
p. 103

Abstract

Read online

Abstract Background Gel-type autologous chondrocyte (Chondron™) implantations have been used for several years without using periosteum or membrane. This study involves evaluations of the clinical results of Chondron™ at many clinical centers at various time points during the postoperative patient follow-up. Methods Data from 98 patients with articular cartilage injury of the knee joint and who underwent Chondron™ implantation at ten Korean hospitals between January 2005 and November 2008, were included and were divided into two groups based on the patient follow-up period, i.e. 13~24-month follow-up and greater than 25-month follow-up. The telephone Knee Society Score obtained during telephone interviews with patients, was used as the evaluation tool. Results On the tKSS-A (telephone Knee Society Score-A), the score improved from 43.52 ± 20.20 to 89.71 ± 13.69 (P Conclusion Gel-type autologous chondrocyte implantation for chondral knee defects appears to be a safe and effective method for both decreasing pain and improving knee function.